318 related articles for article (PubMed ID: 21898753)
1. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
Wang P; Kang D; Cao W; Wang Y; Liu Z
Diabetes Metab Res Rev; 2012 Feb; 28(2):109-22. PubMed ID: 21898753
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
3. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.
Hassan MM; Curley SA; Li D; Kaseb A; Davila M; Abdalla EK; Javle M; Moghazy DM; Lozano RD; Abbruzzese JL; Vauthey JN
Cancer; 2010 Apr; 116(8):1938-46. PubMed ID: 20166205
[TBL] [Abstract][Full Text] [Related]
4. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
5. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
6. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.
Yang WS; Va P; Bray F; Gao S; Gao J; Li HL; Xiang YB
PLoS One; 2011; 6(12):e27326. PubMed ID: 22205924
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease.
Donadon V; Balbi M; Ghersetti M; Grazioli S; Perciaccante A; Della Valentina G; Gardenal R; Dal Mas M; Casarin P; Zanette G; Miranda C
World J Gastroenterol; 2009 May; 15(20):2506-11. PubMed ID: 19469001
[TBL] [Abstract][Full Text] [Related]
8. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
9. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis.
Yang Y; Hu X; Zhang Q; Zou R
Age Ageing; 2016 Nov; 45(6):761-767. PubMed ID: 27515679
[TBL] [Abstract][Full Text] [Related]
10. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.
El-Serag HB; Hampel H; Javadi F
Clin Gastroenterol Hepatol; 2006 Mar; 4(3):369-80. PubMed ID: 16527702
[TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Nie SP; Chen H; Zhuang MQ; Lu M
Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
[TBL] [Abstract][Full Text] [Related]
12. Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study.
Huang TS; Lin CL; Lu MJ; Yeh CT; Liang KH; Sun CC; Shyu YC; Chien RN
J Gastroenterol Hepatol; 2017 Jul; 32(7):1355-1362. PubMed ID: 27930829
[TBL] [Abstract][Full Text] [Related]
13. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
Li Q; Xu H; Sui C; Zhang H
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101781. PubMed ID: 34332136
[TBL] [Abstract][Full Text] [Related]
14. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
15. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; McWilliams RR; Chari ST
Am J Gastroenterol; 2013 Apr; 108(4):510-9; quiz 520. PubMed ID: 23399556
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.
Zhou YY; Zhu GQ; Liu T; Zheng JN; Cheng Z; Zou TT; Braddock M; Fu SW; Zheng MH
Sci Rep; 2016 Sep; 6():33743. PubMed ID: 27642100
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
[TBL] [Abstract][Full Text] [Related]
18. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.
Bosetti C; Franchi M; Nicotra F; Asciutto R; Merlino L; La Vecchia C; Corrao G
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):771-8. PubMed ID: 26013675
[TBL] [Abstract][Full Text] [Related]
19. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis.
Li J; Hernanda PY; Bramer WM; Peppelenbosch MP; van Luijk J; Pan Q
PLoS One; 2015; 10(6):e0127967. PubMed ID: 26030161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
